CRISPR-Cas9 Gene Editing for Refractory Dyslipidemia

A first-in-human treatment using CRISPR-Cas9 to edit the ANGPTL3 gene was well tolerated and substantially reduced both low-density lipoprotein (LDL) cholesterol and triglycerides in a phase 1 trial. The study was reported as a late-breaking…